Skip to content

Sleep Disordered Breathing, Obesity and Pregnancy Study (SOAP)

Sleep Disordered Breathing, Obesity and Pregnancy Study (SOAP)

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02086448
Acronym
SOAP
Enrollment
242
Registered
2014-03-13
Start date
2014-09-30
Completion date
2022-02-28
Last updated
2023-03-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obese, Pregnancy, Sleep Disordered Breathing

Brief summary

The purpose of this study is to better understand how sleep apnea, a common sleep disorder in which a person has one or more pauses in breathing or shallow breaths while sleeping, may affect pregnancy and to determine the effect of Continuous Positive Airway Pressure (CPAP), a treatment that uses mild air pressure to keep the airways open during sleep, for pregnant women with sleep apnea.

Detailed description

Emerging data support a link between sleep disordered breathing (SDB) and adverse pregnancy outcomes, particularly preeclampsia. Furthermore, SDB, which is characterized by intermittent nocturnal hypoxia-reoxygenation as well as sleep disruption, results in endothelial dysfunction and metabolic dysregulation, the same biological pathways that have been associated with adverse pregnancy outcomes. Obesity is a well-known risk factor for both adverse pregnancy outcomes and SDB, and has been associated with the same aforementioned biological aberrations. Therefore, obesity complicates the definition of a causal relationship between SDB and pregnancy outcomes. While some classic cardiovascular risk factors (prehypertension) are certainly relevant in pregnancy, there are also well-established risk factors that are unique to pregnancy (uterine vascular stiffness, placental angiogenic factors). The interplay between SDB, obesity and these unique cardiovascular risk factors remains undefined, and this proposal aims to address this knowledge gap. Without this data, our ability to understand how we can mitigate these risks through the use of therapeutic interventions for SDB, such as CPAP (continuous positive airway pressure), is compromised. To further address this knowledge gap, we will make use of the placenta's ability to accumulate evidence of damage over time and provide a record of maternal vascular health throughout gestation. Numerous placental lesions deriving from maternal vascular disease have been identified and can be readily detected on placental pathology. These lesions can provide a measure of the severity of hypoxic stress experienced by the fetus during gestation. The investigators' central hypothesis is that SDB is an effect modifier that increases maternal cardiovascular risk and placental hypoxic injury in obese pregnant women, and that CPAP treatment during pregnancy will result in an improved cardiovascular risk and placental profile. To test this hypothesis the investigaotrs will identify a cohort of obese women both with and without SDB. The investigators will examine SDB's impact on maternal vascular stiffness (uterine artery Doppler), angiogenesis (pregnancy specific angiogenic factors e.g., sFLT-1) and metabolism (insulin resistance) across pregnancy (Aim 1). The investigators will perform a randomized controlled trial of autotitrating- CPAP verses sham-CPAP in pregnancy to examine the impact of CPAP treatment during pregnancy on cardiovascular risk (Aim 2) and will explore the interplay between SDB, CPAP and evidence of maternal vascular disease and chronic fetal hypoxia by evaluating the placental profile of obese women with and without SDB (Aim 3).

Interventions

DEVICECPAP

CPAP is a device that has a mask worn over the nose that is attached to a device that provides positive airway pressure. CPAP is worn while sleeping, it splints open the airway and prevents apneas (cessation of breathing) and hypopneas (reduced airflow while breathing).

DEVICEsham-CPAP
OTHERSleep hygiene

Information about sleep apnea and healthy sleep. Information about local sleep resources

Sponsors

National Heart, Lung, and Blood Institute (NHLBI)
CollaboratorNIH
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
CollaboratorNIH
Francesca Facco, MD
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* women between 14 0/7 and 20 6/7 weeks gestation at the time of their initial PSG assessment. * Pregnancy and current BMI \>=30 * Self-reported frequent snoring (\>=3x/week over past month) or self-reported non-snorer.

Exclusion criteria

* diagnosis of pregestational diabetes. * self-report a history of sleep apena and who are using or were receommended by a physican to use a PAP device already * twins

Design outcomes

Primary

MeasureTime frameDescription
Uterine Artery Doppler Mean Pulsatility Index -by Ultrasoundearly pregnancy (14-16 weeks gestation)The uterine artery was located using color doppler imaging by placing the ultrasound probe in the right or left iliac fossa in the sagittal plane. The uterine artery was then identified where it crosses the external iliac artery. Doppler waveform was obtained using a sampling gate encompassing the width of the main uterine artery at an angle of insonation of \<30 degrees if possible. The PI was calculated using the formula: maximum-minimum velocity/mean velocity.
Homeostasis Model Assessment of Insulin Resistance (HOMA-IR)-Blood Measurement of Glucose and Insulinearly pregnancy (14-16 weeks gestation)Insulin resistance was calculated using the homeostatic model assessment for insulin resistance (HOMA-IR, fasting insulin (µU/mL) x fasting glucose (mmol/L) /22.5)
Soluble FMS-like Tyrosine Kinase 1 (sFlt-1)/ Placental Growth Factor (PlGF) Ratio-blood Measurementearly pregnancy (14-16 weeks gestation)sFlt-1 is a splice variant of vascular endothelial growth receptor (VEGF) with antiangiogenic properties that is upregulated in preeclampsia. PlGF is an angiogenic cytokine that is highly expressed in the placenta. Low levels have been associated with preeclampsia.

Secondary

MeasureTime frameDescription
Placental Histology and ImmunohistochemistryAfter delivery (expected 37-40 weeks gestation)placental histology and immunohistochemistry

Other

MeasureTime frameDescription
Mean Arterial Blood Pressure (mmHg) Angiogenic Domainearly pregnancy (14-16 weeks gestation)
Soluble Endoglin (sEng , pg/mL)-Blood Measurementlate pregnancy (28-32 weeks gestation)Endoglin is a coreceptor for transforming growth factor beta-1 and beta-3 expressed on syncytiotrophoblasts
Soluble Endoglin (sEng ,pg/mL)-Blood Measurementearly pregnancy (14-16 weeks gestation)Endoglin is a coreceptor for transforming growth factor beta-1 and beta-3 expressed on syncytiotrophoblasts
Pregnancy Outcome DataAt time of delivery (expected 37-40 weeks gestation)Preeclampsia, Gestational diabetes, Gestational age at delivery, Indication for delivery, Birthweight, Cord gases

Countries

United States

Participant flow

Pre-assignment details

A total of 452 individuals were screened and 355 participants consented for this study . Prior to or during the inital study visit, 113 individuals withdrew or were withdrawn from the study. 242 participants completed visit 1 (14 0/7-20 6/7 weeks gestation, mean gestational age 18.1 ± 2.0 weeks), of whom 89 (37%) had an AHI between 5 and 50 and therefore were eligible for randomization.

Participants by arm

ArmCount
Obese, SDB Postive, Sham-CPAP
Sham (non-therapeutic) CPAP sham-CPAP
26
Obese, SDB Postive, CPAP, Phase 1
Therapeutic CPAP CPAP: CPAP is a device that has a mask worn over the nose that is attached to a device that provides positive airway pressure. CPAP is worn while sleeping, it splints open the airway and prevents apneas (cessation of breathing) and hypopneas (reduced airflow while breathing).
25
Obese, SDB Postive, Sleep Hygiene
Sleep hygiene information and local sleep resources Sleep hygiene: Information about sleep apnea and healthy sleep. Information about local sleep resources
20
Obese, SDB Positive, CPAP Phase 2
Therapeutic CPAP
18
Total89

Withdrawals & dropouts

PeriodReasonFG000FG001FG002FG003
Overall StudyWithdrawal by Subject1002

Baseline characteristics

CharacteristicObese, SDB Postive, Sham-CPAPTotalObese, SDB Positive, CPAP Phase 2Obese, SDB Postive, Sleep HygieneObese, SDB Postive, CPAP, Phase 1
Age, Continuous26.4 years
STANDARD_DEVIATION 3.9
29.6 years
STANDARD_DEVIATION 5.5
32.6 years
STANDARD_DEVIATION 4.5
32.0 years
STANDARD_DEVIATION 4.5
28.4 years
STANDARD_DEVIATION 6.5
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants1 Participants0 Participants1 Participants0 Participants
Race (NIH/OMB)
Asian
0 Participants0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Black or African American
19 Participants57 Participants9 Participants13 Participants16 Participants
Race (NIH/OMB)
More than one race
2 Participants2 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
White
5 Participants29 Participants9 Participants6 Participants9 Participants
Sex: Female, Male
Female
26 Participants89 Participants18 Participants20 Participants25 Participants
Sex: Female, Male
Male
0 Participants0 Participants0 Participants0 Participants0 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
EG003
affected / at risk
deaths
Total, all-cause mortality
0 / 250 / 260 / 200 / 18
other
Total, other adverse events
0 / 253 / 260 / 201 / 18
serious
Total, serious adverse events
1 / 250 / 260 / 201 / 18

Outcome results

Primary

Homeostasis Model Assessment of Insulin Resistance (HOMA-IR)-Blood Measurement of Glucose and Insulin

Insulin resistance was calculated using the homeostatic model assessment for insulin resistance (HOMA-IR, fasting insulin (µU/mL) x fasting glucose (mmol/L) /22.5)

Time frame: early pregnancy (14-16 weeks gestation)

ArmMeasureValue (MEAN)Dispersion
Obese, SDB Postive, Sham-CPAPHomeostasis Model Assessment of Insulin Resistance (HOMA-IR)-Blood Measurement of Glucose and Insulin4.5 HOMA-IR scoreStandard Deviation 3.5
Obese, SDB Postive, CPAP, Phase 1Homeostasis Model Assessment of Insulin Resistance (HOMA-IR)-Blood Measurement of Glucose and Insulin4.6 HOMA-IR scoreStandard Deviation 6.4
Obese, SDB Postive, Sleep HygieneHomeostasis Model Assessment of Insulin Resistance (HOMA-IR)-Blood Measurement of Glucose and Insulin3.9 HOMA-IR scoreStandard Deviation 2.2
Obese, SBD Positive, CPAP, Phase 2Homeostasis Model Assessment of Insulin Resistance (HOMA-IR)-Blood Measurement of Glucose and Insulin4.2 HOMA-IR scoreStandard Deviation 3
Primary

Homeostasis Model Assessment of Insulin Resistance (HOMA-IR)-Blood Measurement of Glucose and Insulin

Insulin resistance was calculated using the homeostatic model assessment for insulin resistance (HOMA-IR, fasting insulin (µU/mL) x fasting glucose (mmol/L) /22.5)

Time frame: late pregnancy (28-32 weeks gestation)

ArmMeasureValue (MEAN)Dispersion
Obese, SDB Postive, Sham-CPAPHomeostasis Model Assessment of Insulin Resistance (HOMA-IR)-Blood Measurement of Glucose and Insulin6.3 HOMA-IR scoreStandard Deviation 10.7
Obese, SDB Postive, CPAP, Phase 1Homeostasis Model Assessment of Insulin Resistance (HOMA-IR)-Blood Measurement of Glucose and Insulin3.7 HOMA-IR scoreStandard Deviation 3.6
Obese, SDB Postive, Sleep HygieneHomeostasis Model Assessment of Insulin Resistance (HOMA-IR)-Blood Measurement of Glucose and Insulin3.6 HOMA-IR scoreStandard Deviation 1.8
Obese, SBD Positive, CPAP, Phase 2Homeostasis Model Assessment of Insulin Resistance (HOMA-IR)-Blood Measurement of Glucose and Insulin4.6 HOMA-IR scoreStandard Deviation 6.3
Primary

Soluble FMS-like Tyrosine Kinase 1 (sFlt-1)/ Placental Growth Factor (PlGF) Ratio-blood Measurement

sFlt-1 is a splice variant of vascular endothelial growth receptor (VEGF) with antiangiogenic properties that is upregulated in preeclampsia. PlGF is an angiogenic cytokine that is highly expressed in the placenta. Low levels have been associated with preeclampsia.

Time frame: early pregnancy (14-16 weeks gestation)

ArmMeasureValue (MEAN)Dispersion
Obese, SDB Postive, Sham-CPAPSoluble FMS-like Tyrosine Kinase 1 (sFlt-1)/ Placental Growth Factor (PlGF) Ratio-blood Measurement53.8 RatioStandard Deviation 29.1
Obese, SDB Postive, CPAP, Phase 1Soluble FMS-like Tyrosine Kinase 1 (sFlt-1)/ Placental Growth Factor (PlGF) Ratio-blood Measurement65.1 RatioStandard Deviation 45.8
Obese, SDB Postive, Sleep HygieneSoluble FMS-like Tyrosine Kinase 1 (sFlt-1)/ Placental Growth Factor (PlGF) Ratio-blood Measurement87.0 RatioStandard Deviation 69.1
Obese, SBD Positive, CPAP, Phase 2Soluble FMS-like Tyrosine Kinase 1 (sFlt-1)/ Placental Growth Factor (PlGF) Ratio-blood Measurement88.3 RatioStandard Deviation 45
Primary

Soluble FMS-like Tyrosine Kinase 1 (sFlt-1)/ Placental Growth Factor (PlGF) Ratio-blood Measurement

sFlt-1 is a splice variant of vascular endothelial growth receptor (VEGF) with antiangiogenic properties that is upregulated in preeclampsia. PlGF is an angiogenic cytokine that is highly expressed in the placenta. Low levels have been associated with preeclampsia.

Time frame: late pregnancy (28-32 weeks gestation)

ArmMeasureValue (MEAN)Dispersion
Obese, SDB Postive, Sham-CPAPSoluble FMS-like Tyrosine Kinase 1 (sFlt-1)/ Placental Growth Factor (PlGF) Ratio-blood Measurement30.5 RatioStandard Deviation 28.9
Obese, SDB Postive, CPAP, Phase 1Soluble FMS-like Tyrosine Kinase 1 (sFlt-1)/ Placental Growth Factor (PlGF) Ratio-blood Measurement26.0 RatioStandard Deviation 18.3
Obese, SDB Postive, Sleep HygieneSoluble FMS-like Tyrosine Kinase 1 (sFlt-1)/ Placental Growth Factor (PlGF) Ratio-blood Measurement38.3 RatioStandard Deviation 34.7
Obese, SBD Positive, CPAP, Phase 2Soluble FMS-like Tyrosine Kinase 1 (sFlt-1)/ Placental Growth Factor (PlGF) Ratio-blood Measurement45.9 RatioStandard Deviation 57.3
Primary

Uterine Artery Doppler Mean Pulsatility Index -by Ultrasound

The uterine artery was located using color doppler imaging by placing the ultrasound probe in the right or left iliac fossa in the sagittal plane. The uterine artery was then identified where it crosses the external iliac artery. Doppler waveform was obtained using a sampling gate encompassing the width of the main uterine artery at an angle of insonation of \<30 degrees if possible. The PI was calculated using the formula: maximum-minimum velocity/mean velocity.

Time frame: early pregnancy (14-16 weeks gestation)

ArmMeasureValue (MEAN)Dispersion
Obese, SDB Postive, Sham-CPAPUterine Artery Doppler Mean Pulsatility Index -by Ultrasound1.0 Mean PIStandard Deviation 0.3
Obese, SDB Postive, CPAP, Phase 1Uterine Artery Doppler Mean Pulsatility Index -by Ultrasound1.0 Mean PIStandard Deviation 0.3
Obese, SDB Postive, Sleep HygieneUterine Artery Doppler Mean Pulsatility Index -by Ultrasound1.0 Mean PIStandard Deviation 0.3
Obese, SBD Positive, CPAP, Phase 2Uterine Artery Doppler Mean Pulsatility Index -by Ultrasound1.0 Mean PIStandard Deviation 0.3
Primary

Uterine Artery Doppler Mean Pulsatility Index -by Ultrasound

The uterine artery was located using color doppler imaging by placing the ultrasound probe in the right or left iliac fossa in the sagittal plane. The uterine artery was then identified where it crosses the external iliac artery. Doppler waveform was obtained using a sampling gate encompassing the width of the main uterine artery at an angle of insonation of \<30 degrees if possible. The PI was calculated using the formula: maximum-minimum velocity/mean velocity.

Time frame: late pregnancy (28-32 weeks gestation)

ArmMeasureValue (MEAN)Dispersion
Obese, SDB Postive, Sham-CPAPUterine Artery Doppler Mean Pulsatility Index -by Ultrasound0.9 Mean PIStandard Deviation 0.2
Obese, SDB Postive, CPAP, Phase 1Uterine Artery Doppler Mean Pulsatility Index -by Ultrasound0.8 Mean PIStandard Deviation 0.3
Obese, SDB Postive, Sleep HygieneUterine Artery Doppler Mean Pulsatility Index -by Ultrasound0.8 Mean PIStandard Deviation 0.2
Obese, SBD Positive, CPAP, Phase 2Uterine Artery Doppler Mean Pulsatility Index -by Ultrasound0.7 Mean PIStandard Deviation 0.1
Secondary

Placental Histology and Immunohistochemistry

placental histology and immunohistochemistry

Time frame: After delivery (expected 37-40 weeks gestation)

Population: Placental collection and analysis was not performed due to inadequate staffing and personnel issues

Other Pre-specified

Mean Arterial Blood Pressure (mmHg) Angiogenic Domain

Time frame: early pregnancy (14-16 weeks gestation)

Other Pre-specified

Mean Arterial Blood Pressure (mmHg) Angiogenic Domain

Time frame: late pregnancy (28-32 weeks gestation)

Other Pre-specified

Pregnancy Outcome Data

Preeclampsia, Gestational diabetes, Gestational age at delivery, Indication for delivery, Birthweight, Cord gases

Time frame: At time of delivery (expected 37-40 weeks gestation)

Other Pre-specified

Soluble Endoglin (sEng , pg/mL)-Blood Measurement

Endoglin is a coreceptor for transforming growth factor beta-1 and beta-3 expressed on syncytiotrophoblasts

Time frame: late pregnancy (28-32 weeks gestation)

Other Pre-specified

Soluble Endoglin (sEng ,pg/mL)-Blood Measurement

Endoglin is a coreceptor for transforming growth factor beta-1 and beta-3 expressed on syncytiotrophoblasts

Time frame: early pregnancy (14-16 weeks gestation)

Source: ClinicalTrials.gov · Data processed: Feb 12, 2026